February 8, 2016
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director, President andChief Executive Officer

SymBio and Teikyo Heisei University enter into aJoint Research and Development Agreement for an Anti-cancer Drugusing the TTR1 Nano-agonist Molecule
SymBio Pharmaceuticals Limited (head office: Tokyo, "SymBio") announced today that it entered into
an agreement with Teikyo Heisei University ("the Agreement") to collaborate on the research anddevelopment of an innovative anti-cancer drug which uses the TTR1 nano-agonist molecule1.
Under the Agreement’s terms, SymBio will provide its resources to implement preclinical andIND-enabling studies in collaboration with Teikyo Heisei University. SymBio also secures an option
to enter into an exclusive license agreement with Teikyo Heisei University to globally develop andcommercialize this innovative drug globally.
The team led by Dr. Isao Ishida, Professor of the Faculty of Pharmaceutical Sciences, Teikyo Heisei
University, discovered an antibody against TRAIL-R1 that is expressed on the surface of cancer cells orcancer stem cells, and modified its form to impart more efficient anti-cancer activity (TTR1 nanoagonist). A drug delivery technique using an expression system in Bifidobacterium2 was developed
which enables the TTR1 nano-agonist to act selectively on hypoxic cancer tissue, with confirmation of
the anti-cancer activity and safety of this new anti-cancer drug in animal models.
"The research being done by Professor Ishida and his team is a very innovative therapeutic approachfor cancer that combines several proprietary techniques, Bifidobacterium and the TTR1 nano-agonist
molecule utilizing the nature of cancer and cancer stem cells that are preferentially living underhypoxic condition. We look forward to the start of collaboration with Professor Ishida to deliver thisfirst-in-class anti-cancer drug to patients in need on a global basis,” said Fuminori Yoshida,
Representative Director, President and CEO of SymBio.
By leveraging our extensive experience in compressing development timelines and securing early drug
approvals, bringing this innovative TTR1 therapeutic anti-cancer drug to patients is a reflection of ourmission to address unmet medical needs as we continue our transformation to a global
biopharmaceutical company.
Conclusion of this collaboration agreement with Teikyo Heisei University will have no significant
impact on the Company’s earnings forecast for fiscal year ended December 31, 2016.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
Note: For an explanation of technical terms used in this press release and additional information on
Teikyo Heisei University or SymBio, please refer to the following.

TTR1 nano-agonist1 TRAIL is a member of the tumor necrosis factor (TNF) family that exerts its
apoptotic activity in human cells when it trimerizes by binding to its transmembrane receptors,
TRAIL-R1 and TRAIL-R2. It is difficult to form a trimeric structure using conventional anti-TRAIL-R1
antibodies, and thus apoptosis-inducing ability is typically weak. Camelids (e.g. camels, alpacas,llamas) produce functional antibodies devoid of light chains of which the single N-terminal domain is
fully capable of antigen binding. These single-domain antibody fragments (VHHs or sdAb) haveseveral advantages for biotechnological applications: they are well expressed in microorganisms, havea high stability and solubility, and can penetrate tissues relatively easily. Trivalent anti-TRAIL-R1
single-domain antibodies (TTR1: an abbreviation for Trivalent anti-TRAIL-R1) used in ourcollaboration have agonistic activities and induce apoptosis, thus we call them TTR1 nano-agonist(s).

Bifidobacterium2 Bifidobacterium is a genus of Gram-positive bacteria, and are one of the major
genera of bacteria that make up the colon flora in mammals, with probiotic activity limited toanaerobic environments. Bifidobacterium strains are important probiotics and widely used in the foodindustry (e.g. yogurt). As many types of cancer (specifically solid tumors such as pancreatic cancer)
grow in a hypoxic environment, intravenously administered Bifidobacterium expressing the TTR1
nano-agonist molecule will selectively live in cancer tissue and effectively kill cancer cells via TTR1
nano-agonist molecule expression.

2

About Teikyo Heisei University
Teikyo Heisei University is an incorporated educational institution established in 1987 (with its namechanged from Teikyo University of Technology in 1995). The university’s motto is "to develop very
creative, powerful human resources full of human love through acquisition of extensive knowledge andpractical abilities in a special field based on the spirit of practical science" in the Faculties ofPharmaceutical Science, Modern Life, Health Care, Health and Medical Science, and Community
Health Care, and the Graduate Schools of Pharmaceutical Science, Environmental Information,
Health Science, and Clinical Psychology. As an urban-type university, campuses are in Ikebukuro,Nakano, Chiba, Chiharadai and Makuhari.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. The company’s underlying corporate mission is to “deliver hope to patients in need” as it
aspires to be a leading specialty biopharmaceutical company dedicated to addressing underserved
medical needs with main therapeutic focus in oncology, hematology and pain management.

3